Introduction
Hemophilia B is the X-linked bleeding disorder caused by mutations in the coagulation factor IX (F.IX) gene. In its severe form (F.IX activity o1% of normal), the disease is characterized by frequent spontaneous bleeding into joints and soft tissues, and bleeds into critical closed spaces can be fatal. Current treatment is based on intravenous infusion of recombinant or plasma-derived F.IX protein concentrate, which is costly and inconvenient. Furthermore, bleeds are treated rather than prevented unless prophylactic factor infusions are carried out. In 3-4% of patients, an immune response develops resulting in inhibitory antibodies ('inhibitors') that neutralize F.IX activity, thereby complicating treatment. 1 Studies in large animal models have shown that gene therapy is a promising alternative that can provide continuous supply of F.IX in vivo.
2 Our published data demonstrate sustained long-term F.IX expression via adeno-associated viral (AAV) vector-mediated gene transfer to the liver or skeletal muscle, and the safety of both approaches has been tested in Phase I clinical trials. [2] [3] [4] [5] AAV serotype 2 vectors are based on a nonpathogenic, replication defective parvovirus with a 4.7-kb single-stranded DNA genome. Advantages of this vector include absence of viral coding sequences, low innate immunogenicity, production without helper virus, and efficient in vivo gene transfer to nondividing target cells (eg hepatocytes or muscle fibers) with mostly episomal persistence of the vector genome. 6 However, several studies demonstrated formation of antibodies to the F.IX transgene product after AAV-mediated gene transfer. [7] [8] [9] [10] [11] [12] The risk for such immune responses depended on the underlying F.IX mutation, route of vector administration, vector dose and serotype. 13 Inhibitor formation to F.IX was most frequently observed after intramuscular (i.m.) injection of vector in animals that lacked tolerance to the F.IX transgene product such as mice with F.IX gene deletion, dogs with F.IX nonsense mutation, or animals that received transfer of a F.IX transgene that was not species-specific. 8, 10, 12, 14 Use of a muscle-specific promoter did not prevent antibody formation to F.IX. 15 Anti-F.IX formation upon muscle gene delivery is due to an adaptive, CD4 + T-celldependent immune response which is absent in CD4-or Rag1-deficient mice. 9, 14 Transient immune suppression using cyclophosphamide successfully prevented inhibitor formation. 8, 10, 11 In contrast, sustained expression of canine F.IX in hemophilia B dogs with a F.IX missense mutation was obtained after i.m. administration, which did not require immune suppression unless very high vector doses were injected. 4, 11 After comparing vector doses per site of injection between different treated hemophilia B dogs and experiments with a more efficient AAV serotype-1 vector, we suspected local F.IX antigen doses in transduced muscle to be a critical parameter for the risk of inhibitor formation. 7, 11 Based on these observations, only subjects with F.IX missense mutations were enrolled in the trial based on muscle delivery, and the vector dose per site of i.m. injection was limited. 5 Hepatic gene expression of F.IX via AAV or plasmid vector has been shown to direct sustained F.IX expression without inhibitor formation in hemophilia B mice and dogs with deletion and nonsense mutations. 3, [16] [17] [18] [19] This route of vector administration was found to induce immune tolerance to the F.IX transgene product. 20 Tolerance induction was favored by higher levels of F.IX expression and was associated with induction of regulatory CD4 + T cells that could suppress antibody formation to F.IX after adoptive transfer. 20 Tolerance induction was successful in several inbred strains of mice with different MHC haplotypes and in outbred mice. Here, we provide further evidence that tolerance induction by hepatic gene transfer is associated with absence of T helper cell responses to F.IX, which is dependent on levels of transgene expression. Furthermore, we used outbred CD-1 mice, which show some of the strongest T-cell responses to human F.IX (hF.IX) antigen, to study immune responses to F.IX in the context of muscledirected gene transfer. A robust local immune response resulting in CD4 + T-cell and B-cell activation in draining lymph nodes (LN) of injected skeletal muscle was largely responsible for induction of an antibody response to hF.IX. Immune responses were augmented with increased vector doses and were initially dominated by a Th1 response shifting to Th2 over time. IgG responses neutralized systemic hF.IX expression while expression by muscle fibers continued. Human F.IX antigen reappeared in circulation at high vector doses by 1.5 months, which, however, coincided with the onset of an inflammatory response in transduced muscle. These data further delineate the role of the route of vector administration and levels of transgene expression in immune responses to F.IX and point toward a major impact of local antigen presentation.
Results
Lack of T helper cell responses after tolerance induction to hF.IX by hepatic AAV gene transfer
We have previously documented that hepatic gene transfer mediated by AAV vector-induced tolerance to hF.IX. 20 Hepatic transduced mice failed to form antibody to hF.IX even after challenge with hF.IX protein formulated in complete Freund's adjuvant. After a second challenge with hF.IX in adjuvant, splenocytes from tolerized mice failed to proliferate after in vitro restimulation with hF.IX, while cells from naïve control mice showed hF.IX-specific proliferation after the repeated immunization. 20 As shown in Table 1 , splenocytes from mice tolerized by hepatic AAV-hF.IX administration also failed to secrete IL-2, IFN-g, IL-10 cytokines after in vivo challenge with hF.IX formulated in adjuvant followed by in vitro restimulation with hF.IX (suggesting absence of Th1 and Th2 responses), whereas controls had mouse strain-dependent cytokine responses, which were particularly robust in C3H mice (H-2 k haplotype) and in outbred CD-1 mice.
In other experiments, we had shown that CD-1 mice formed anti-hF.IX at low vector doses in liver-directed gene transfer, while higher levels of hepatic transgene expression (as determined by vector dose and promoter strength) favored tolerance induction. 20 In a further dose escalation study, CD-1 mice received hepatic gene transfer with 2 Â 10 10 (n ¼ 4), 1 Â 10
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(n ¼ 25), or 1 Â 10 12 (n ¼ 8) AAV-EF1a-hF.IX vector genomes (vg)/ animal. At the lowest dose, neither hF.IX expression nor antibodies were detected (Table 2) . At the mid-dose, none of the animals had detectable hF.IX expression, and 6/25 mice formed anti-hF.IX (low levels of IgG2a and additionally IgG1 in 4/6 mice, see Table 2 ). At the highest vector dose, 8/8 animals showed systemic hF.IX expression (4-120 ng/ml), with 3/8 mice also having detectable (IgG1) antibody to hF.IX (Table 2) . Those mice with detectable anti-hF.IX had the lowest levels of expression (data not shown). Therefore, these antibodies may have partially neutralized expression, or, alternatively, these animals may have had insufficient gene transfer for efficient tolerance induction. T helper cell responses (Th1 and Th2, as measured by cytokine release assay) to hF.IX were detectable in animals that had developed antibody to hF.IX after receiving the mid vector dose (1 Â 10 11 vg of AAV-EF1a-hF.IX, Table 2 ). Cytokine responses were undetectable at the highest vector dose (Table 2 ; note that mice analyzed in Table 2 had not been subjected to adjuvant boost). Naïve or AAV-EF1a-hF.IX or AAV-ApoE/hAAT-hF.IX-transduced mice (1 Â 10 11 to 2 Â 10 12 vector genomes (vg)/animal as indicated) were boosted twice with hF.IX formulated in Freund's adjuvant (FA; first challenge with complete FA1.5-2.5 months after gene transfer followed by incomplete FA 1 month later) and killed on day 5 after the second boost. Lymphocyte cultures (pooled from n ¼ 3-5 mice/strain) were stimulated with hF.IX protein (10 mg/ml media). For all strains, mock-stimulated cells had undetectable release of IL-2 and IL-10 and released low amounts of IFN-g, which were subtracted from values for hF.IX-stimulated culture. For outbred CD-1 mice, lymphocyte cultures were set up for individual animals (n ¼ 5), and results were averaged. . Circulating levels of hF.IX were detected at day 9 post gene delivery but became undetectable by day 14 in all animals ( Figure 1a ). Antibodies to hF.IX (IgG1 and IgG2a) were found at low levels in plasma of some animals as early as day 9 post gene delivery, while by day 14, all mice had detectable anti-hF.IX IgG1 and IgG2a. IgG1 anti-hF.IX levels (7-10 mg/ml) were persistently high for days 14-30, while IgG2a anti-hF.IX levels were high initially (10 mg/ml at day 14), but gradually declined to low levels (B1 mg/ml) by day 30 (Figure 1b, c) . Consequently, there was a substantial change in the IgG1/IgG2a ratio over time (0.8:1 at day 14 to 10:1 at day 30; Figure 1d ). Analysis of tissue sections from injected muscles showed normal morphology without inflammatory infiltrate or tissue damage at days 14 and 30 after vector injection ( Figure  2a-d) . Immunofluorescence staining of hF.IX at these time points demonstrated hF.IX expression by transduced muscle fibers, indicating that systemic expression was not lost because of a cytotoxic T lymphocyte (CTL) response or because of promoter shut down. Taken together, these data indicate that AAV-mediated hF.IX gene transfer to skeletal muscle was successful and that the transient nature of hF.IX expression was due to a neutralizing antibody response.
ELISPOT assays for antibody and cytokine secreting cells show a local immune response in skeletal muscle
Following gene transfer, hF.IX antigen is present at the site of transgene expression (skeletal muscle) and is also systemically delivered. The latter could lead to lymphocyte activation in the spleen as described for intravenous protein infusion. 21 We wanted to investigate whether systemic or local hF.IX antigen is the substrate for induction of an anti-hF.IX response. In order to study the activation of hF.IX-specific B cells in lymphoid organs, we adapted an ELISPOT technique to quantitate hF.IX-specific antibody secreting cells (ASCs) isolated from draining LN of the injected muscle (inguinal and popliteal LN) or from the spleen. At day 14, IgG1-and IgG2a-ASCs were found in the draining LN but were nearly undetectable in the spleen (Figure 3a , b, e). By day 30, low, but measurable numbers of IgG1-ASCs were found in spleens and LN (Figure 3c ). IgG2a-ASCs were detectable in both organs (but were higher in the draining LN) at day 14 and declined to undetectable by day 30 consistent with ELISA data on circulating IgG2a anti-hF.IX levels. Human F.IX-ASCs in naïve control mice were undetectable by these assays (o1/10 6 cells, data not shown).
Activation of B cells is dependent on CD4 + T helper cell responses to hF.IX, and IgG subclass switching is influenced by the local cytokine milieu that is generated by a particular subset of T helper cells. We used ELISPOT to quantitate IFN-g and IL-4-secreting cells in LN and spleens. In naïve control mice, IL-4-secreting cells were undetectable (o2 SPU/10 6 cells), and IFN-g-secreting cells were found with a frequency of o50 SPU/10 6 cells in the spleen and o20 SPU/10 6 cells in LN, which was independent of stimulation with hF.IX antigen (n ¼ 5, data not shown). Substantial IFN-g responses were detected in the draining LNs, which increased further in response to in vitro restimulation with hF.IX protein, while IFN-g-secreting cells were not detected above background among splenocytes at day 14 ( Figure 4a , e). By day 30, however, numbers of IFN-g-secreting cells increased in the spleen, and responses were now similar for LN cells and splenocytes ( Figure 4c ). IL-4-secreting cells were low in numbers at day 14, increased by day 30, and were consistently higher in the LN than in the spleen (Figure 4d ). For each sample with a response above background, numbers of detectable cytokine-secreting cells increased upon in vitro re-stimulation with hF.IX (data not shown). When mice with anti-hF.IX formation after hepatic gene transfer (n ¼ 6) were assayed by these ELISPOT assays, only a weak IFN-g response was measurable in spleens but not inguinal or popliteal LN (data not shown).
Immune responses in muscle are vector dose-dependent
The effect of vector dose on immune responses to hF.IX after i.m. administration was tested in the following set of experiments. CD-1 mice received i.m. injections of AAV-CMV-hF.IX vector at doses of 2 Â 10 10 and 1 Â 10 11 vg/mouse (n ¼ 5/dose). Results were compared to high dose (1 Â 10 12 vg/mouse) described above. Antibodies to hF.IX were readily detected by ELISA assay on day 14 in all animals at all three vector doses. Average serum High vector dose to muscle may overcome antibodymediated neutralization of hF.IX expression, but also cause inflammation and CD8 + T-cell activation at late time points
We also performed longer-term follow-up studies (14-18 weeks) for all three vector doses injected into muscle (n ¼ 4-5 animals/dose). All dose groups showed sustained formation of antibodies to hF.IX, which neutralized systemic expression for the duration of the experiment in the low-and mid-dose cohorts, and from weeks 2-6 also in the high-dose cohort (Figure 6a-i) . Interestingly, in the high-dose cohort, systemic hF.IX antigen levels reappeared by 7-8 weeks after vector administration in 3/5 mice (Figure 6g ). Levels subsequently increased in these three mice to B300 to 1700 ng/ml (Figure 6g ), but declined again in one animal to B30% of peak levels by 10 weeks after gene transfer. Muscle tissues of mice from this high-dose cohort were analyzed. At day 67, two animals with and one without systemic hF.IX expression were killed. All three mice continued to show substantial expression of hF.IX by muscle fibers, but had also developed an inflammatory immune response in transduced muscles (Figure 2e, f and data not shown). Inflammatory infiltrates were targeting muscle fibers and contained CD8 + T cells (Figure 2g ). There was also evidence for muscle regeneration (ie presence of central nuclei, Figure 2f , h, i) and fibrosis (not shown). While fibers with central nuclei were often negative for hF.IX expression by immunohistochemistry, there were clearly also a number of regenerated fibers that had transgene expression (Figure 2h, i) . When the remaining two mice were analyzed at day 120, inflammation and muscle regeneration had further intensified (Figure 2j-l) , indicating a long-lived inflammatory reaction, CD8 + cell infiltrate, and destruction of muscle fibers. At this time point, a large number of regenerated fibers with central nuclei were obvious (Figure 2j, k) . However, inflammation only marginally reduced the proportion of transgene expressing muscle fibers between days 67 and 120 after gene transfer (Figure 7) . On further analysis, inflammatory infiltrates in transduced muscle were seen by B2 months at mid and high, but not low vector doses (Figure 5f ).
Additional CD-1 mice received i.m. injections at the three vector doses (n ¼ 2-4/dose) in order to test for inhibitory activity of anti-hF.IX. At all doses, high-titer inhibitory antibodies to hF.IX (410 BU) were formed by 1-2 months after vector administration as determined by Bethesda assay (Table 3) . These were sustained for at least 4.5 months at low and mid vector doses ( Table 3) . The two mice injected with 1 Â 10 12 vg expressed hF.IX levels of B500 ng/ml by 5 months after gene transfer (Table 3) . Although anti-hF.IX was still detectable by ELISA (data not shown), no inhibitory antibody was detectable by Bethesda assay at this late time point (Table  3) . Serial dilution of plasma samples followed by measurement of activated partial thromboplastin time (aPTT) coagulation time suggested biological activity of the expressed hF.IX transgene product (Table 3 and Figure 8 ), indicating that it is possible to overcome the 
Discussion
The risk of immune response to the F.IX transgene product in a gene-based treatment strategy is influenced by a number of factors, including the route of vector administration. 12 In this study, we used hF.IX as the transgene product expressed from an AAV vector. We know from previous studies that mice are capable of forming T-and B-cell responses if this neo-antigen is introduced by gene transfer. Therefore, such studies are helpful in improving our understanding of how immune responses against F.IX may develop in vivo. Use of an outbred strain such as CD-1 mice reduces the possibility of generating data that are strain-or MHC haplotypespecific. Furthermore, cytokine release assays using mice immunized with hF.IX protein indicated that CD-1 mice had strong T-cell responses to hF.IX.
Weak immune responses or tolerance induction after hepatic gene transfer
Despite the ability of CD-1 mice to form antibody to hF.IX, such responses were infrequent and low-titer in the context of hepatic compared to muscle-directed gene transfer. While some mice formed anti-hF.IX at the middose (mostly low-titer, ie o1 mg/ml), high-dose hepatic Immune response to F.IX in muscle L Wang et al gene transfer yielded sustained expression, which was either not associated with antibody formation or was only partially neutralized by anti-hF.IX. Previously, we showed that systemic expression is sustained for at least 4-6 months. 20 Data presented in Tables 1 and 2 combined with our published results illustrate that adequate levels of hepatic transgene expression favored tolerance induction, which was associated with absence or substantial reduction in Th1 and Th2 responses to hF.IX antigen. Using an ovalbumin transgene product, we had recently provided direct evidence induction of CD4 + T-cell tolerance by hepatic AAV gene transfer involving anergy and deletion mechanisms. 22 Consistent with our published data on hF.IX, low levels of hepatic hF.IX transgene expression elicited Th1 responses, while increased expression from increased vector doses caused a shift toward Th2 or tolerance. 20 Overall, we failed to induce a robust immune response to hFIX by hepatic gene transfer in CD-1 mice, and relatively low levels of transgene expression were sufficient to downregulate immune responses. Earlier, we demonstrated that expression levels 430 ng/ml were sufficient to achieve robust tolerance after hepatic gene transfer with AAV vector, which was maintained after challenge with antigen in complete Freund's adjuvant. 20 Our success rate of tolerance induction to hF.IX by hepatic gene transfer in different strains of mice correlated with the level of transgene expression that could be achieved in a particular strain (highest in C57BL/6 and lowest in CD-1), and inversely correlated with the strength of T-cell responses to hF.IX as judged by cytokine release assays in immunized control mice (Table 1 and published data). 20 
Strong local immune responses after muscle gene transfer
In the context of muscle-directed gene transfer, all animals injected at all three vector doses formed antibody to hF.IX, suggesting induction of immune responses over a wide range of hF.IX expression in skeletal muscle. Our data indicate that an adaptive immune response to F.IX after gene transfer to skeletal muscle is initiated locally, resulting in antigen presentation and lymphocyte activation in the draining LN of the transduced tissue. Over time, antibody responses were reduced in the LN, and the spleen also became involved in anti-hF.IX production. At day 14, Th1 responses were dominant with high levels of IgG2a production and strong IFN-g responses. However, this did not result in an inflammatory response, likely because of inefficient CD8 + T-cell activation. 9, 14, 23, 24 It is thought that because of unproductive transduction of dendritic cells and lack of innate immunity to the AAV vector, there is inefficient MHC class I presentation of F.IX peptides to CD8 + T cells by professional antigen presenting cells (APCs). [23] [24] [25] However, lack of inflammation during the first month after gene transfer and shift toward Th2 immunity did not prevent subsequent activation of CD8 + T cells and inflammation at later time points (Figure 3 ). Consistent with this interpretation, we found that a local immune response to ovalbumin transgene product caused activation of ovalbumin-specific CD4 + T cells at first (day 5) exclusively in draining LN, but not in the spleen or nondraining LN. 26 Others published similar data for muscle transduction with an AAV vector expressing influenza virus hemagglutinin. 24 Data from this current study provide an explanation for our previous observations in hemophilia B dogs, which suggested an increased risk of inhibitor formation in animals that received high doses per site of i.m. injection of AAV vector expressing canine F.IX. 11 Consequently, the dose per site of injection was limited in a Phase I clinical trial on muscle-directed AAV-F.IX gene transfer in subjects with severe hemophilia B. 5 
Implications for antigen processing in muscle
In the primary immune response, T-cell activation in the draining LN is a consequence of uptake and processing of F.IX antigen in the muscle tissue by dendritic cells followed by migration to this lymphoid organ and subsequent antigen presentation. 27 While the activation signal in AAV gene transfer is currently unknown, it is now clear that exposure of APCs to F.IX antigen in the muscle has different consequences compared to the liver. The composition of dendritic cells and other APCs or the microenvironment in the muscle may be responsible for increased likelihood of immune responses. Alternatively or in addition to differences in APC function, properties of the F.IX protein may have unique consequences in muscle. Although we cannot entirely rule out a role for post-translational modifications, their involvement appears unlikely for the following reasons. A similar difference in immunogenicity between the muscle and liver is observed for F.IX, a 1 -antitrypsin, and ovalbumin, three unrelated proteins. Furthermore, AAV-hF.IX gene transfer to muscle of animals transgenic for hF.IX expressed in the liver (the normal site of F.IX synthesis) or the skin does not break tolerance. 28, 29 However, accumulation and binding of muscle-derived F.IX to the extracellular matrix surrounding muscle fibers may contribute to undesired antigen uptake and processing by APCs as described for cell surface-associated ovalbumin, leading to an immune response in animals not tolerant to the F.IX antigen.
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Role of antigen levels in muscle gene transfer While neutralizing antibody formation to hF.IX occurred over a wide range of vector doses in the context of gene transfer to skeletal muscle, this response was partially overcome within 2 months in the high-dose group. We have previously demonstrated that anti-hF.IX caused by i.m. administration of AAV serotype 1 vector in C57BL/6 mice had become undetectable within 7-12 weeks, Immune response to F.IX in muscle L Wang et al concurrent with the emergence of hF.IX antigen in the circulation. This required higher vector doses (X4 Â 10 12 vg/kg), while anti-hF.IX formation was sustained after low-dose injection. 7 At an intermittent dose of 2 Â 10 12 AAV-1 vg/kg, coexisting systemic hF.IX and anti-hF.IX expression was found (Mingozzi and Herzog, unpublished results). Similarly, our new data with AAV-2 vector (which in our hands is approximately 10-to 20-fold less efficacious than serotype 1 vector in muscle) show emerging hF.IX antigen levels by 7-8 weeks at a dose of 4 Â 10 13 vg/kg, which is not seen at lower AAV-2 vector doses. 8, 9, 14 Taken together, these results indicate that F.IX antigen levels produced by transduced muscle tissue are a critical parameter that determines whether neutralization of systemic expression by antibody formation is sustained. Levels of expression o0.2 mg/ml are typically not sufficient to overcome the antibody response, while higher levels (0.2-3.5 mg/ml) may promote decline of the antibody response over time. 7, 14 Out data show that this can lead to elimination of inhibitors and gain of F.IX activity in the circulation. At even higher levels of expression (2-8 mg/ml, which was achieved by high-dose AAV-1 administration), anti-hF.IX formation may be completely absent (D Sabatino, personal communication). These results are consistent with data presented by others using human or canine F.IX transgenes delivered to muscle of hemophilia B mice by AAV-1 vector. 31, 32 It is possible that persistent systemic delivery of high antigen levels prevent or overcome immune response otherwise initiated locally in the muscle. These observations are reminiscent of immune tolerance protocols for treatment of inhibitors in hemophilia. In this case, the inhibitory antibody is eliminated by frequent high-dose administration of coagulation factor protein combined with injection of human immunoglobulin, resulting in induction of split tolerance. 33 Nonetheless, antigen levels required for tolerance induction by hepatic gene transfer are considerably lower (1-2 log) compared to muscle gene transfer. 
Inflammatory responses
Previously, we demonstrated absence of inflammatory and CD8 + T-cells responses after muscle-directed AAVhF.IX gene transfer, which was assayed for up to 90 days after vector administration.
14 These experiments were performed in a different strain of mice (C57BL/6) and with vector dose intermediate between mid and high doses tested here. Results presented here demonstrate that AAV-F.IX gene transfer can activate CD8 + T cells. In contrast to adenoviral gene transfer, the ensuing inflammation caused only partial loss of transgene expressing cells, which may be explained by lower efficiency in activation of CTLs, less efficient Th1 help, or increase of transgene expression over time (secondary to slow uncoating of AAV-2 vector particles). 9, 23, 34 Interestingly, the animal with the sharpest decline in transgene expression had a late increase in IgG2a production, a Th1-dependent subclass of immunoglobulin, suggesting a late increase in Th1 immunity, which can be correlated with the inflammatory response. Given that the inflammatory reaction occurred long after gene transfer, and that these animals are not subject to natural infection with AAV, CD8 + T-cell responses were most likely directed against the hF.IX antigen. Presence of regenerated muscle fibers expressing the transgene product and the fact that much of hF.IX expression was maintained during severe inflammation and destruction of muscle fibers may reflect some level of transduction of muscle fiber precursor cells after high-dose AAV vector administration. Additionally, expression may be turned on in muscle fibers that had initially not been productively transduced. The resulting additional expression could contribute to prolonged or chronic inflammation, which was sustained for 42 months. The prolonged nature of the inflammation may be associated with immune regulation, which would explain why expression ultimately was not eliminated. The substantial dose advantage of the liver over muscle in AAV-2 gene transfer, which is typically seen for hemophilia B dogs and C57BL/6 and some other strains of mice, was not upheld in CD-1 mice. In this strain, muscle gene transfer gave higher levels of expression and hepatic gene transfer at the same vector dose. While efficacy of AAV2-F.IX gene transfer to muscle appeared fairly consistent with earlier results from other strains, there is much greater variability for hepatic gene transfer among different strains of mice.
Since skeletal muscle-derived expression has limited capacity to induce tolerance to a transgene product representing a neo-antigen, muscle-directed gene transfer may have to be supplemented by transient immune suppression (eg using cyclophosphamide). 8, 10 Additional studies are required to characterize antigen presentation and activation signals, which ultimately lead to T-cell activation in draining LNs of skeletal muscle.
Materials and methods

Construction of AAV vector
AAV serotype-2 vector was produced in an adenovirusfree system by triple-transfection of HEK-293 cells as described. 35 Vector was purified by repeated cesium chloride density gradient centrifugation, and viral titers determined by quantitative dot blot hybridization. 35 AAV-CMV-hF.IX for muscle-directed and AAV-EF1a-hF.IX vector for hepatic gene transfer were as described, with hF.IX expression driven by CMV or EF1a enhancer/ promoter. 14, 20 Animal experiments C57BL/6, C3H/HeJ, BALB/c, and CD-1 mice that had previously received hepatic AAV gene transfer for hF.IX expression were identical to those animals in our earlier publication. 20 These animals were used for cytokine release assay (results are summarized in Table 1 ). All subsequent experiments were carried out on CD-1 mice (Charles River Breeding Laboratories, Wilmington, MA, USA). Male mice (4-6 weeks old) were anesthetized and AAV-CMV-hF.IX vector was injected into the tibialis anterior (25 ml) and the quadriceps muscle (50 ml) of each leg using a Hamilton syringe for muscle gene delivery. 35 AAV-EF1a-hF.IX was delivered through splenic capsule injection in a volume of 100 ml in order to achieve delivery to the portal circulation for hepatic gene transfer. 20 Blood samples were collected from the retroorbital plexus in microhematocrit capillary tubes. To collect mouse splenocytes and LN cells, mice were killed, spleens and inguinal and popliteal nodes were collected and pooled. Tissues were treated with collagenase D for a short period of time and red blood cells were lysed by ammonia-chloride-potassium (ACK) treatment.
Analyses of mouse plasma samples
Levels of hF.IX in plasma samples were determined by ELISA, and antibody concentrations specific to hF.IX were measured by immunoglobulin subclass-specific immunocapture assay as published. 9 To determine coagulation activity of the hF.IX transgene product, samples were serially diluted in F.IX-deficient human plasma (Organon Technika, Durham, NC, USA) followed by assay for aPTT using a fibrometer (Fibrosystem, BBL, Cockeysville, MD, USA). 8 Clotting times were compared to normal mouse plasma obtained from CD-1 mice that had not received gene transfer. Inhibitory antibodies to hF.IX were measured by Bethesda assay. Briefly, samples were serially diluted in imidazole buffer and mixed with an equal volume of normal human plasma (Verify 1, Organon Technika) and incubated at 371C for 2 h. Residual coagulation activity was determined by aPTT. Contribution of murine F.IX to coagulation activity was also determined for each dilution (using plasma from untransduced mice) and subtracted. One Betheda Unit (BU) is equivalent to 50% residual activity.
ELISPOT for IFN-g and IL-4-secreting cells
This assay was performed using ELISPOT kits for mouse IFN-g and IL-4 cyokines from BD Biosciences. Plates were coated with capture antibodies against mouse IFN-g or IL-4. Splenocytes or LN cells were applied into coated wells in RPMI1640 medium/10% fetal bovine serum (RPMI1640/10) and incubated for several days (3 Immune response to F.IX in muscle L Wang et al days for IFN-g and 5 days for IL-4, respectively). After removing cells by PBS wash, horseradish peroxidase (HRP)-conjugated anti-mouse IFN-g or IL-4 was added for 1-h incubation at room temperature (RT), and spots were detected with 3-amino-9-ethylcarbazole (AEC) substrate solution. Plates were air-dried and analyzed using the ImmunoSpot Analyzer (Hightech Instruments, Edgemont, PA, USA). To assure accuracy, some plates were also counted manually. Results were calculated as spot-forming units (SFU) per 10 6 total cells.
ELISPOT assay for hF.IX-specific B-cell responses
Briefly, Multiscreen-HA Plates (BD Bioscience, San Diego, CA, USA) were coated with hF.IX protein (Mononine, Armour Pharmaceutical Co., Kankakee, IL, USA) in a volume of 100 ml per well at a concentration of 20 mg/ml. Wells were then blocked with RPMI1640/10 media for at least 1 h. Isolated mouse splenoytes and LN cells were added into wells in RPMI1640/10 medium and incubated overnight at 371C. Cells were removed by washing with PBS, and antibodies against mouse IgG1 or IgG2a (HRP-conjugated; Roche Applied Science, Indianapolis, IN, USA; 1:1000) were applied for 1 h at RT. Plates were then developed and analyzed as described above. For naïve CD-1 mice, no anti-hF.IX-secreting cells were detectable by this assay (o1 SFU per 10 6 cells).
Cytokine release assay
Lymphocytes extracted from spleens, portal and inguinal lymph nodes were isolated as described above and pooled for in vitro T-cell assays (3-5 animals/experimental cohort). Lymphocytes were cultured in 2-MLC medium (DMEM, 2% heat-inactivated fetal calf serum, 1 mM sodium pyruvate, 10 mM HEPES, 0.1 mM nonessential amino acids, 10 À6 M 2-mercaptoethanol, and antibiotics) for 5 days in the absence (mock) or presence of hF.IX antigen (10 mg/ml). Conditioned media were analyzed for cytokine secretion by ELISA using reagents from Pharmingen (San Diego, CA, USA). IL-2 and IFN-g were measured after 3 days of in vitro restimulation, and IL-10 after 5 days. For outbred CD-1 mice, lymphocytes from four mice were processed and assayed individually, and cytokine release was averaged.
Histochemical analysis
Mouse muscle tissue was snap-frozen in liquid isopentene as described. 35 Cryosections of muscle tissue were analyzed for presence of hF.IX by immunofluorescence staining as previously reported. 9 Tissue section was also analyzed by hematoxylin/eosin staining. Stained sections were viewed with the Eclipse E800 microscope (Nikon Corporation, Tokyo, Japan). Images were captured with a Cool Snap-Pro camera and analyzed with Image Pro-Plus software (both from Media Cybernetics, Silver Spring, MD, USA).
